238 related articles for article (PubMed ID: 25100280)
1. Type of MRI contrast, tissue gadolinium, and fibrosis.
Do C; Barnes JL; Tan C; Wagner B
Am J Physiol Renal Physiol; 2014 Oct; 307(7):F844-55. PubMed ID: 25100280
[TBL] [Abstract][Full Text] [Related]
2. Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents.
Lohrke J; Frisk AL; Frenzel T; Schöckel L; Rosenbruch M; Jost G; Lenhard DC; Sieber MA; Nischwitz V; Küppers A; Pietsch H
Invest Radiol; 2017 Jun; 52(6):324-333. PubMed ID: 28323657
[TBL] [Abstract][Full Text] [Related]
3. Gadolinium-Induced Fibrosis.
Todd DJ; Kay J
Annu Rev Med; 2016; 67():273-91. PubMed ID: 26768242
[TBL] [Abstract][Full Text] [Related]
4. Nephrogenic systemic fibrosis-like effects of magnetic resonance imaging contrast agents in rats with adenine-induced renal failure.
Fretellier N; Bouzian N; Parmentier N; Bruneval P; Jestin G; Factor C; Mandet C; Daubiné F; Massicot F; Laprévote O; Hollenbeck C; Port M; Idée JM; Corot C
Toxicol Sci; 2013 Jan; 131(1):259-70. PubMed ID: 22977165
[TBL] [Abstract][Full Text] [Related]
5. Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis.
Reilly RF
Clin J Am Soc Nephrol; 2008 May; 3(3):747-51. PubMed ID: 18287249
[TBL] [Abstract][Full Text] [Related]
6. Influence of excess ligand on Nephrogenic Systemic Fibrosis associated with nonionic, linear gadolinium-based contrast agents.
Semelka RC; Prybylski JP; Ramalho M
Magn Reson Imaging; 2019 May; 58():174-178. PubMed ID: 30471330
[TBL] [Abstract][Full Text] [Related]
7. Nephrogenic systemic fibrosis in Japan: advisability of keeping the administered dose as low as possible.
Tsushima Y; Takahashi-Taketomi A; Endo K
Radiology; 2008 Jun; 247(3):915-6. PubMed ID: 18487548
[No Abstract] [Full Text] [Related]
8. Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis?
Boyd AS; Sanyal S; Abraham JL
J Am Acad Dermatol; 2010 Feb; 62(2):337-42. PubMed ID: 19939504
[TBL] [Abstract][Full Text] [Related]
9. Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a Research on Adverse Drug Events and Reports (RADAR) report.
Edwards BJ; Laumann AE; Nardone B; Miller FH; Restaino J; Raisch DW; McKoy JM; Hammel JA; Bhatt K; Bauer K; Samaras AT; Fisher MJ; Bull C; Saddleton E; Belknap SM; Thomsen HS; Kanal E; Cowper SE; Abu Alfa AK; West DP
Br J Radiol; 2014 Oct; 87(1042):20140307. PubMed ID: 25230161
[TBL] [Abstract][Full Text] [Related]
10. Skin gadolinium following use of MR contrast agents in a rat model of nephrogenic systemic fibrosis.
Haylor J; Schroeder J; Wagner B; Nutter F; Jestin G; Idée JM; Morcos S
Radiology; 2012 Apr; 263(1):107-16. PubMed ID: 22344402
[TBL] [Abstract][Full Text] [Related]
11. Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis.
Piera-Velazquez S; Louneva N; Fertala J; Wermuth PJ; Del Galdo F; Jimenez SA
Ann Rheum Dis; 2010 Nov; 69(11):2017-23. PubMed ID: 20570839
[TBL] [Abstract][Full Text] [Related]
12. Response to the FDA's May 23, 2007, nephrogenic systemic fibrosis update.
Kanal E; Broome DR; Martin DR; Thomsen HS
Radiology; 2008 Jan; 246(1):11-4. PubMed ID: 17855656
[No Abstract] [Full Text] [Related]
13. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.
Soulez G; Bloomgarden DC; Rofsky NM; Smith MP; Abujudeh HH; Morgan DE; Lichtenstein RJ; Schiebler ML; Wippold FJ; Russo C; Kuhn MJ; Mennitt KW; Maki JH; Stolpen A; Liou J; Semelka RC; Kirchin MA; Shen N; Pirovano G; Spinazzi A
AJR Am J Roentgenol; 2015 Sep; 205(3):469-78. PubMed ID: 26295633
[TBL] [Abstract][Full Text] [Related]
14. Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation.
Edward M; Quinn JA; Burden AD; Newton BB; Jardine AG
Radiology; 2010 Sep; 256(3):735-43. PubMed ID: 20663970
[TBL] [Abstract][Full Text] [Related]
15. Incidence of immediate gadolinium contrast media reactions.
Prince MR; Zhang H; Zou Z; Staron RB; Brill PW
AJR Am J Roentgenol; 2011 Feb; 196(2):W138-43. PubMed ID: 21257854
[TBL] [Abstract][Full Text] [Related]
16. Gadolinium contrast agent-induced CD163+ ferroportin+ osteogenic cells in nephrogenic systemic fibrosis.
Swaminathan S; Bose C; Shah SV; Hall KA; Hiatt KM
Am J Pathol; 2013 Sep; 183(3):796-807. PubMed ID: 23867799
[TBL] [Abstract][Full Text] [Related]
17. Nephrogenic systemic fibrosis: evidence for oxidative stress and bone marrow-derived fibrocytes in skin, liver, and heart lesions using a 5/6 nephrectomy rodent model.
Wagner B; Tan C; Barnes JL; Ahuja S; Davis TL; Gorin Y; Jimenez F
Am J Pathol; 2012 Dec; 181(6):1941-52. PubMed ID: 23041060
[TBL] [Abstract][Full Text] [Related]
18. Nephrogenic systemic fibrosis: A survey of the use of gadolinium-based contrast agents in Ghana.
Piersson AD; Gorleku PN
Radiography (Lond); 2017 Nov; 23(4):e108-e113. PubMed ID: 28965904
[TBL] [Abstract][Full Text] [Related]
19. Tissue gadolinium deposition in renally impaired rats exposed to different gadolinium-based MRI contrast agents: evaluation with inductively coupled plasma mass spectrometry (ICP-MS).
Sato T; Ito K; Tamada T; Kanki A; Watanabe S; Nishimura H; Tanimoto D; Higashi H; Yamamoto A
Magn Reson Imaging; 2013 Oct; 31(8):1412-7. PubMed ID: 23643157
[TBL] [Abstract][Full Text] [Related]
20. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update.
Idée JM; Port M; Dencausse A; Lancelot E; Corot C
Radiol Clin North Am; 2009 Sep; 47(5):855-69, vii. PubMed ID: 19744600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
